These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 39298477)

  • 1. CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting.
    Lim K; Kan WL; Nair PC; Kutyna M; Lopez AF; Hercus T; Ross DM; Lane S; Fong CY; Brown A; Yong A; Yeung D; Hughes T; Hiwase D; Thomas D
    PLoS One; 2024; 19(9):e0310641. PubMed ID: 39298477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
    Muramatsu H; Makishima H; Jankowska AM; Cazzolli H; O'Keefe C; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Blood; 2010 Mar; 115(10):1969-75. PubMed ID: 20008299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
    Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
    J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.
    Loh ML; Sakai DS; Flotho C; Kang M; Fliegauf M; Archambeault S; Mullighan CG; Chen L; Bergstraesser E; Bueso-Ramos CE; Emanuel PD; Hasle H; Issa JP; van den Heuvel-Eibrink MM; Locatelli F; Stary J; Trebo M; Wlodarski M; Zecca M; Shannon KM; Niemeyer CM
    Blood; 2009 Aug; 114(9):1859-63. PubMed ID: 19571318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
    Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
    Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia.
    Hecht A; Meyer JA; Behnert A; Wong E; Chehab F; Olshen A; Hechmer A; Aftandilian C; Bhat R; Choi SW; Chonat S; Farrar JE; Fluchel M; Frangoul H; Han JH; Kolb EA; Kuo DJ; MacMillan ML; Maese L; Maloney KW; Narendran A; Oshrine B; Schultz KR; Sulis ML; Van Mater D; Tasian SK; Hofmann WK; Loh ML; Stieglitz E
    Haematologica; 2022 Jan; 107(1):178-186. PubMed ID: 33375775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.
    Bernard V; Gebauer N; Dinh T; Stegemann J; Feller AC; Merz H
    Int J Clin Exp Pathol; 2014; 7(4):1667-76. PubMed ID: 24817963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
    Wei Y; Kanagal-Shamanna R; Zheng H; Bao N; Lockyer PP; Class CA; Darbaniyan F; Lu Y; Lin K; Yang H; Montalban-Bravo G; Ganan-Gomez I; Soltysiak KA; Do KA; Colla S; Garcia-Manero G
    Leukemia; 2022 Aug; 36(8):2097-2107. PubMed ID: 35697791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
    Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
    J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
    Watanabe J; Sato K; Osawa Y; Horiuchi T; Kato S; Hikota-Saga R; Maekawa T; Yamamura T; Kobayashi A; Kobayashi S; Kimura F
    Int J Hematol; 2018 Jul; 108(1):47-57. PubMed ID: 29600428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.
    Javadi M; Richmond TD; Huang K; Barber DL
    J Biol Chem; 2013 Jul; 288(27):19459-70. PubMed ID: 23696637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Srsf2
    Xu JJ; Chalk AM; Wall M; Langdon WY; Smeets MF; Walkley CR
    Leukemia; 2022 Dec; 36(12):2883-2893. PubMed ID: 36271153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
    Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
    Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
    Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
    [No Abstract]   [Full Text] [Related]  

  • 16. Age-related mutations and chronic myelomonocytic leukemia.
    Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
    Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.
    Geissler K; Jäger E; Barna A; Gurbisz M; Graf T; Graf E; Nösslinger T; Pfeilstöcker M; Machherndl-Spandl S; Stauder R; Zebisch A; Sill H; Öhler L; Kusec R; Hörmann G; Valent P
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
    Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
    Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired expression of
    Nakata Y; Ueda T; Nagamachi A; Yamasaki N; Ikeda KI; Sera Y; Takubo K; Kanai A; Oda H; Sanada M; Ogawa S; Tsuji K; Ebihara Y; Wolff L; Honda ZI; Suda T; Inaba T; Honda H
    Blood; 2017 Apr; 129(15):2148-2160. PubMed ID: 28209720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.